CO-NEWMONT-CORPORATION
8.2.2024 14:31:30 CET | Business Wire | Press release
Newmont Corporation (NYSE: NEM, TSX: NGT, ASX: NEM, PNGX: NEM) and Project C.U.R.E. announce a five-year agreement to deliver medical supplies and life-saving training for healthcare providers in developing countries and communities near Newmont mining operations. Under the agreement, Newmont commits to an annual contribution of $200,000 over the next five years, totaling $1 million.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240208935869/en/
Newmont and Project C.U.R.E.’s partnership has created a positive economic ripple effect across 36 countries. (Graphic: Business Wire)
“Creating a positive impact on more than 10 million people globally, through our partnership with Project C.U.R.E. is something we are incredibly proud of,” said Suzy Retallack, Newmont’s Chief Safety and Sustainability Officer. “For nearly two decades, our partnership has helped deliver support to host communities near our operations and around the world. We look forward to continuing to leverage our combined global reach to make a strong impact where it is needed most.”
Since 2005, Newmont has partnered with Project C.U.R.E. to distribute more than $42 million worth of much-needed medical supplies and equipment through multiple sponsorship initiatives. Highlights of the partnership include:
- Funding 108 shipping containers of medical equipment to 36 countries.
- Impacting more than two million patients through Newmont’s support of the C.U.R.E. Cargo program.
- Training more than 440 medical professionals, through the C.U.R.E. College program, in resource-limited environments to reduce neonatal and maternity morbidity and mortality.
- Contributing $5 million to support humanitarian efforts relating to the ongoing war in Ukraine, providing direct support to Project C.U.R.E., the American Red Cross and International Medical Corps.
- Delivering 164 C.U.R.E. kits – suitcase-sized, pre-packed kits of essential medical supplies – through Newmont employees to healthcare facilities in Ethiopia, Ghana, Indonesia, Mexico, Nicaragua, Peru and Suriname.
“We are proud of our partnership with the team at Newmont. For nearly two decades, we have worked together to save lives and strengthen the healthcare infrastructure for millions of people,” said Dr. Douglas Jackson, President and CEO of Project C.U.R.E. “In countries like Ghana and Suriname and now Mexico, Guatemala and others, we have established a figurative gold standard for corporate social responsibility and making our communities healthier, happier and more hopeful.”
Also, as part of Newmont’s partnership, employees around the world participate in myriad volunteer opportunities – logging hundreds of hours of time and service helping sort supplies at the Project C.U.R.E. warehouse, packing and unloading containers, and carrying medical kits to communities near Newmont operations.
About Project C.U.R.E.
Established in a garage in Evergreen, Colorado in 1987, Project C.U.R.E. has grown to be the world’s largest distributor of donated medical supplies and equipment to people living in developing countries. Since 2000, Project C.U.R.E. has delivered more than $1 billion of medical relief to save the lives of people facing poverty, disasters and violence. Project C.U.R.E. has worked in 138 countries, establishing an incredible footprint of medical relief around the world.
As a registered 501(c)(3), Project C.U.R.E.’s goal is to bridge the staggering health resource gaps in the developing world by empowering doctors and nurses with the tools they need—medical supplies and equipment—to treat disease, deliver vaccines, perform life-changing surgeries, and ensure safe childbirth. On average, Project C.U.R.E. delivers five forty-foot containers of donated medical relief each week.
About Newmont
Newmont is the world’s leading gold company and a producer of copper, zinc, lead, and silver. The company’s world-class portfolio of assets, prospects and talent is anchored in favorable mining jurisdictions in Africa, Australia, Latin America & Caribbean, North America, and Papua New Guinea. Newmont is the only gold producer listed in the S&P 500 Index and is widely recognized for its principled environmental, social, and governance practices. Newmont is an industry leader in value creation, supported by robust safety standards, superior execution, and technical expertise. Founded in 1921, the company and has been publicly traded since 1925.
At Newmont, our purpose is to create value and improve lives through sustainable and responsible mining. To learn more about Newmont’s sustainability strategy and initiatives, go to www.newmont.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208935869/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
